We are doing this study to find out if an experimental drug called LB-1908 (the study drug) is a safe and effective treatment for different types of gastrointestinal cancers. The study drug is custom-made for each participant from their own white blood cells or T-cells. We collect these cells using a procedure called apheresis.

Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer, Esophageal Cancer, or Pancreatic Adenocarcinoma
adenocarcinoma

Adults ages 18-75 who:

• Are diagnosed with gastric cancer, gastroesophageal junction (GEJ) cancer, esophageal cancer, or pancreatic
  adenocarcinoma
• Test positive for Claudin 18.2 protein
• Have received at least one round of previous treatment for their cancer

For more information about who can join this study, please contact the study team at cci-trialreferrals@duke.edu or 919-681-6468.

If you choose to join this study, you will:

• Have a tumor biopsy to test for a particular protein (Claudin 18.2) in your body
• Undergo apheresis to collect your white blood cells or T-cells to make the study drug
• Receive lympho-depleting chemotherapy
• Check into the hospital for a stay during which you will get the study drug through an intravenous (IV) infusion
• Have physical exams, blood draws, and give urine samples
• Have imaging scans (CT and/or MRI)
• Have heart tests (ECG)